Our Promise to you:
Premier global microbiological solutions, extensive collection of products.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Ovarian cancer remains one of the most mortal gynecological malignancies in the world. Targeted therapy is a recent drug innovation and aims at blocking specific proteins or genes. Targeted therapy is predicted to be a less toxic and more effective than older forms of therapeutic strategy for ovarian cancer.
Fig.1 current main therapeutic targets of ovarian cancer.
Targeted therapy is different to non-specific treatments like chemotherapy that involves employment of non-specific intracellular toxins that inhibit the process of cell division. Targeted therapy could reduce the side- effects due anti-mitotic damage to the normal cells. Poly ADP ribose polymerase (PARP) inhibitors have recently garnered interest in ovarian cancer treatment. PARP inhibitors and anti-VEGF monoclonal antibodies have been approved for maintenance and treatment as effective targeted drugs for advanced or recurrent ovarian.
|Target||Types||Agent||Manufacturer||Start Marketing Date|
|PARP||Small molecule||Lynparza||AstraZeneca& Merck||2014|
|PARP||Small molecule||Zejula||Tesaro& Merck||2017|
In the field of cancer treatment, it was viewed that the bacteria have the ability to deliver tumor-specific anticancer genes and the potential tumor-targeting antitumor capability. We have expertise in gene knockout, knock-in/replacement and site-directed mutagenesis. Creative Biogene is able to provide you the comprehensive oncolytic bacteria genome editing service, including traditional recombineering system, CRISPR/Cas 9 system and site-specific recombination system.
• Fast turnaround time, lower price
• higher efficiency and success rate
• Rich experience
• Markerless genome editing
• Easy selection: no selectable marker is required
1. Lu-Yao, Guan, Yuan, & Lu. (2018). New developments in molecular targeted therapy of ovarian cancer. Discovery Medicine.
2. Muallem, M. Z. . (2017). Targeted therapy in ovarian cancer. a comprehensive systematic review of literature. Anticancer Research, 37(6), 2809-2815.